SynthesisBritish journal of clinical pharmacology2004
The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol.
Synthesis in British journal of clinical pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis.Canadian respiratory journal · 2018Pooled it
- Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment.The Journal of allergy and clinical immunology · 2016Pooled it
- Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.American journal of respiratory and critical care medicine · 2013Trial
- Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.Lancet (London, England) · 2009Trial
- beta-Adrenergic receptor polymorphisms and response to salmeterol.American journal of respiratory and critical care medicine · 2006Trial
- Development of Inhaled GABAACS pharmacology & translational science · 2022Article
- Article
- Comparison of the effectiveness and safety of formoterol versus salmeterol in the treatment of patients with asthma: A systematic review and meta-analysis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2015Review
- Asthma pharmacogenetics and the development of genetic profiles for personalized medicine.Pharmacogenomics and personalized medicine · 2015Review
- Emerging role of long acting muscarinic antagonists for asthma.British journal of clinical pharmacology · 2014Review
- Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine.The Journal of allergy and clinical immunology · 2014Review
- Pharmacogenetics and the development of personalized approaches for combination therapy in asthma.Current allergy and asthma reports · 2013Review
- Reply: Adverse effects of long-acting beta-agonists on airway hyperresponsiveness.American journal of respiratory cell and molecular biology · 2013Article
- Pharmacogenetics of asthma controller treatment.The pharmacogenomics journal · 2013Article
- Article
- Effects of the β-agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of β2-adrenergic receptors with N-terminal polymorphisms.Cell biology international · 2012Article
- The role of pharmacogenomics in improving the management of asthma.The Journal of allergy and clinical immunology · 2010Review
- Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism.Current opinion in pulmonary medicine · 2010Review
- Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment.Yonsei medical journal · 2009Article
- Role of ADRB2 gene polymorphism in asthma and response to beta(2)-agonists in Polish children.Journal of applied genetics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe relationship between beta2-adrenoceptor polymorphisms and bronchoprotective response with long-acting beta2-adrenoceptor agonists is unknown.
methodsWe retrospectively analysed data from six placebo-controlled randomized studies in corticosteroid treated asthmatics where formoterol or salmeterol were administered over a 1-2-week period, with prior 1-2 week washout, assessing the primary end point of methacholine PD20 and adenosine monophosphate PC20, following first and last dose, expressed as doubling dose difference from placebo.
resultsThere was no significant heterogeneity between the different studies. Patients who had homozygous or heterozygous genotypes containing the arginine-16 polymorphism (Arg16-Arg16 or Arg16-Gly16) had greater bronchoprotective subsensitivity compared with the homozygous glycine-16 genotype (Gly16-Gly16), amounting to a mean doubling dose difference of 1.49 (95% CI 0.50, 2.48), after the last dose. Subsensitivity of response was greater with formoterol than salmeterol after the last dose in all genotypes, especially with the arginine-16 polymorphism, amounting to a doubling dose difference of 3.00 (95% CI 1.01, 4.99) between formoterol and salmeterol.
conclusionsOur retrospective analysis showed that the arginine-16 polymorphism was associated with subsensitivity of response for bronchoprotection, which was greater for formoterol than salmeterol. A prospective study will be required in order to further evaluate these findings, particularly to assess whether these differences are mirrored by exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.